Page 112 - 82_02

Cannabinoid analogs in the treatment of pain
8. Pertwee RG. Cannabinoid receptors and pain. Prog.
Neurobiol 2001;63: 569-611.
9. Vega R. Opioides: neurobiología, usos médicos y
adicción. Elementos 2005;12(60): 11-23.
10. Sugiura T, Kondo S, Sukagawa A, et al. 2-
Arachidonoylglycerol: a posible endogenous
cannabinoid receptor ligand in brain. Biochem.
Biophys Res Commun 1995;215: 89-97.
11. Mechoulam R, et al. Identification of an endogenous 2-
monoglyceride, present in canine gut, that binds to
cannabinoid receptors. Biochem Pharmacol 1995;50:
83-90.
12. Hanus L, et al. 2-Arachidonyl glyceryl ether, an
endogenousagonist of the cannabinoid CB1 receptor.
Proc Natl Acad Sci USA 2001;98: 3662-5.
13. Porter AC, et al. Characterization of a novel
endocannabinoid, virodhamine, with antagonist
activity at the CB1 receptor. J Pharmacol Exp Ther
2002; 301:1020-4.
14. Huang SM, et al. An endogenous capsaicin-like
substance with high potency at recombinant and
native vanilloid VR1 receptors. Proc Natl Acad Sci
USA 2002;99: 8400-5.
15. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-
Carmona M, Le Fur G, Caput D, Ferrara P. An amino-
terminal variant of the central cannabinoid receptor
resulting from alternative splicing. J Biol Chem 1995
Feb 24;270(8): 3726-31
16. Howlett AC. Cannabinoid inhibition of adenylate
cyclase: Biochemistry of the response in
neuroblastoma cell membranes. Mol Pharmacol
1985;27: 429-36.
17. Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X,
Calandra B, Rinaldi-Carmona M, Le Fur G and
Casellas P. Activation of mitogen-activated protein
kinases by stimulation of the central cannabinoid
receptor CB1. Biochem J 1995;312: 637-41.
18. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P,
Devane WA, Felser CC, Herkenham M, Mackie K,
Martin BR, Mechoulam R, Pertwee RG. International
union of pharmacology, XXVII. Clasification of
cannabinoid receptors. Pharmacol Rev 2002;54: 161-
202.
19. Ameri A. The effects of cannabinoids on the brain.
Progress in neurobiology 1999;58: 315-48.
20. Di Marzo V, Matias I. Endocannabinoid control of
food intake and energy balance. Nature Nsci 2005;8:
585-9.
21. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie
K, Blond O, Lai Y, Ma AL, Mitchell RL. Comparison
of the pharmacology and signal transduction of the
human cannabinoid CB1 and CB2 receptors. Mol
Pharmacol 1995;48: 443-50.
22. Howlett AC. Pharmacology of cannabinoid receptors.
Ann Rev Pharmacol Toxicol 1995; 35: 607-34.
23. "Part III: Pain Terms, A Current List with Definitions
@Real Academia Nacional de Farmacia. Spain
and Notes on Usage" (pp 209-214) Classification of
Chronic Pain, Second Edition, International
Association for the study of Pain (IASP) Task Force
on Taxonomy, edited by H. Merskey and N. Bogduk,
IASP Press, Seattle, 1994.
24. Turk DC, Okifuji A. Pain terms and taxonomies. In:
Loeser D, Butler SH, Chapman JJ, et al. Bonica's
management of pain (3 ed.). Lippincott Williams &
Wilkins 2001; pp. 18-25.
25. Berkow R, Beers MH. Manual Merck de información
médica. Madrid: Océano Grupo Editorial 1999
26. Ferrer M, Ribes C. Farmacología de la migraña. Jaen:
Formación Alcalá 2006.
27. Stovnera LJ, Zwarta JA, Hagena K, Terwindtd GM,
Pascuale J. Epidemiology of headache in Europe.
European Journal of Neurology 2006; 13: 333-345
28. Romero J, Lastres Becker I, de Miguel R, Berrendero
F, Ramos JA, Fernández-Ruiz JJ. The endogenous
cannabinoid system and the basal ganglia:
biochemical, pharmacological and therapeutic aspects.
Pharm Ther 2002; 95: 137-52.
30. Manzanares J, Corchero J, Romero J, Fernández-Ruiz
JJ, Ramos JA, Fuentes JA. Pharmacological and
biochemical interactions between opioid and
cannabinoids. Trends Pharmacol Sci 1999; 20: 287-
94.
31. Malan TP, Ibrahim MM, Deng H, Liu Q, Mata HP,
Vanderah T, et al. CB2 cannabinoid receptor-mediated
peripheral antinociception. Pain 2001; 93: 239-45.
32. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon
A. N-(2-hydroxyethyl)- hexadecanamide is orally
active in reducing edema formation and inflammatory
hyperalgesia by down-modulating mast cell activation.
Eur J Pharmacol 1996; 300: 227-36.
33. Jhaveri MD, Sagar DR, Elmes SJR, Kendall DA,
Chapman V. Cannabinoid CB2 receptor-mediated
antinociception in models of acute and chronic pain.
Mol Neurobiol 2007; 36: 26-35.
34. Pertwee RG. Cannabinoids and multiple sclerosis.
Pharmacol Ther 2002; 95: 165-74.
35. Arias E, Gallego-Sandín S, Villarroya M, Garcia AG,
Lopez MG. Unequal neuroprotection afforded by the
acetylcholinesterase inhibitors galantamine, donepezil,
and rivastigmine in SH-SY5Y neuroblastoma cells:
role of nicotinic receptors. J Pharmacol Exp Ther
2005;315(3): 1346-53.
36. Tiraboschi P, Hansen, LA, Thal LJ, Corey-Bloom J.
The importance of neuritic plaques and tangles to the
development and evolution of AD. Neurology 2004;
62(11): 1984-9.
37. Recuero M, Serrano E, Bullido MJ, Valdivieso F.
Abeta production as consequence of cellular death of a
human neuroblastoma overexpressing APP. Febs Lett
2004;570: 114-8.
38. Horiguchi T, Uryu K, Giasson BI, Ischiropoulos H,
LightFoot R, Bellmann C, Richter-Landsberg C, Lee
227